Advertisement

Advertisement
Geriatric Oncology
Cost of Care

Self-Reported Financial Distress Among Older Adults With Cancer Prior to Initiating Therapy

In a single-institution study reported in JCO Oncology PracticeSmith Giri, MD, MHS, and colleagues found that 27% of patients with cancer...

Breast Cancer
Immunotherapy

Guideline Update Offers New Directions About Trastuzumab Emtansine for HER2-Positive Breast Cancer

About 10% to 20% of newly diagnosed breast cancers demonstrate overexpression of the HER2 protein. Since the introduction of trastuzumab, several new HER2-targeted...

Issues in Oncology

Does Supplementation With Vitamin D Reduce the Risk of Developing Advanced Cancer?

The Vitamin D and Omega-3 Trial (VITAL), which was completed in 2018, found that vitamin D did not reduce overall incidence of cancer...


Advertisement
Breast Cancer
Legislation

Study Finds Medicaid Expansion in Louisiana Increased Early-Stage Breast Cancer Diagnosis and Access to Treatment

A study by Quyen D. Chu, MD, MBA, FACS, and colleagues published in the journal Cancer investigated how expansion of the Medicaid provision...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Prostate Cancer

Cynthia Menard, MD, on Prostate Cancer: PSMA PET- and CT-Guided Intensification of Radiotherapy

Hepatobiliary Cancer
Pancreatic Cancer

FDA Pipeline: Fast Track Designations in Liver and Pancreatic Cancers

Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designations to novel agents in the treatment of liver and pancreatic cancers. Fast Track Designation for SRF388 in Liver Cancer The FDA granted Fast Track designation to SRF388 for the treatment of patients with...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Lung Cancer
Immunotherapy

Benjamin Besse, MD, PhD, on NSCLC: Neoadjuvant Atezolizumab for Resectable Disease

Leukemia

Comanagement of Induction Therapy for Acute Promyelocytic Leukemia by Experts and Community Practices

In a study reported in JCO Oncology Practice, Anand P. Jillella, MD, and colleagues found that physician education on the main causes of death during induction treatment for acute promyelocytic leukemia (APL)—and comanagement of cases with expert physicians—resulted in a low early mortality rate...

Leukemia

Comanagement of Induction Therapy for Acute Promyelocytic Leukemia by Experts and Community Practices

In a study reported in JCO Oncology Practice, Anand P. Jillella, MD, and colleagues found that physician education on the main causes of death during induction treatment for acute promyelocytic leukemia (APL)—and comanagement of cases with expert physicians—resulted in a low early mortality rate...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Prostate Cancer

Cynthia Menard, MD, on Prostate Cancer: PSMA PET- and CT-Guided Intensification of Radiotherapy

Solid Tumors
Immunotherapy

ESMO Asia 2020: Novel PD-L1 Antibody Shows Activity in Advanced MSI-H/dMMR Tumors

Envafolimab (also known as KN035), a novel PD-L1 antibody, demonstrated antitumor activity and was safe in patients with diverse, advanced microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) tumors, according to findings presented by Shen et al at the ESMO Asia Virtual Congress...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...